PRX-102
PB-102-F01 & PB-102-F02
Phase 3 small_molecule completed
Quick answer
PRX-102 for Fabry Disease is a Phase 3 program (small_molecule) at Protalix BioTherapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Protalix BioTherapeutics
- Indication
- Fabry Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed